Cosmos Health Accelerates U.S. Expansion: Liv18 Phase 1 Execution Complete; Production and Sales Commencing April 2026; Expected to Generate $5M+ in Annual Revenue at ~75% ...

Phase 1 complete: product development, packaging, and initial commercial setup finalized ahead of schedule Production commencing April 2026: GMP-certified, FDA-registered, UL-audited U.S.
Seeking Alpha

Cosmos Health Announces Accelerating Customer Growth, Improving Unit Economics and Robotic Expansion Supporting $40M in Additional Annual Revenue

CHICAGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced continued ...

Cosmos Health Continues US Expansion with Q2 Launch of Cur18 - a Clinically Studied, Patented Curcumin Next-Gen Therapy Supplement Delivering 39× Higher Bioavailability and ...

Clinically studied curcumin formulation demonstrating significantly enhanced absorption versus standard 95% curcuminoid extracts. Derived predominantly from turmeric (~98.5%), maintaining a ...
Morningstar

Cosmos Health Reports No Impact from Iran and Middle East Conflict; Revenue Continues at All-Time High Levels; NOOR U.S. Expansion on Track to Exceed $12 Million Within 12 Months

Cosmos Health operates through a diversified international platform spanning Europe, North America, and other key regions. The conflict in the Middle East and recent geopolitical developments have had ...